May 10, 2019
Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Puma Biotechnology finished first quarter 2019 with Non-GAAP adjusted net income of $8.1M
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Puma Biotechnology
May 3, 2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,announced that on May 3, 2019 the Compensation Committee of Puma’s Boardof Directors approved the grant of inducement restricted stock unitawards covering an aggregate of 49,125 shares of Puma common stock tonine new non-executive employees.
April 25, 2019
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m.…
April 9, 2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 3, 2019 the Compensation Committee of…
April 4, 2019
Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT…
April 1, 2019
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
LOS ANGELES & CASTRES, France–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement…
March 18, 2019
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting
Oral Plenary Presentation Receives SGO Presidential Award LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that…
March 18, 2019
Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast…
March 14, 2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
announced that on March 12, 2019 the Compensation Committee of Puma’s
Board of Directors approved the grant of inducement restricted stock…
July 21, 2017
Diplomat to distribute Puma Biotechnology’s new cancer drug
Diplomat Pharmacy will distribute Puma Biotechnology’s new product, Nerlynx, a kinase inhibitor approved by the US Food and Drug Administration (FDA).